» Articles » PMID: 23212076

Dual Roles of PKM2 in Cancer Metabolism

Overview
Specialties Biochemistry
Biophysics
Date 2012 Dec 6
PMID 23212076
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer cells have distinct metabolism that highly depends on glycolysis instead of mitochondrial oxidative phosphorylation alone, known as aerobic glycolysis. Pyruvate kinase (PK), which catalyzes the final step of glycolysis, has emerged as a potential regulator of this metabolic phenotype. Expression of PK type M2 (PKM2) is increased and facilitates lactate production in cancer cells, which determines whether the glucose carbons are degraded to pyruvate and lactate or are channeled into synthetic processes. Modulation of PKM2 catalytic activity also regulates the synthesis of DNA and lipids that are required for cell proliferation. However, the mechanisms by which PKM2 coordinates high-energy requirements with high anabolic activities to support cancer cell proliferation are still not completely understood. This review summarizes the biological characteristics of PKM2 and discusses the dual role in cancer metabolism as well as the potential therapeutic applications. Given its pleiotropic effects on cancer biology, PKM2 represents an attractive target for cancer therapy.

Citing Articles

IGF-1 Signaling Modulates Oxidative Metabolism and Stress Resistance in ARPE-19 Cells Through PKM2 Function.

Ravera S, Puddu A, Bertola N, Verzola D, Russo E, Maggi D Int J Mol Sci. 2025; 25(24.

PMID: 39769402 PMC: 11727907. DOI: 10.3390/ijms252413640.


The impact of glucose metabolism on inflammatory processes in sepsis-induced acute lung injury.

Cheng S, Li Y, Sun X, Liu Z, Guo L, Wu J Front Immunol. 2024; 15:1508985.

PMID: 39712019 PMC: 11659153. DOI: 10.3389/fimmu.2024.1508985.


Bioinformatics analysis of PSAT1 loss identifies downstream pathways regulated in EGFR mutant NSCLC and a selective gene signature for predicting the risk of relapse.

Biyik-Sit R, Waigel S, Andreeva K, Rouchka E, Clem B Oncol Lett. 2024; 29(1):9.

PMID: 39512505 PMC: 11542166. DOI: 10.3892/ol.2024.14755.


Effective-Component Compatibility of Bufei Yishen Formula III Suppresses Mitochondrial Oxidative Damage in COPD: Via Pkm2/Nrf2 Pathway.

Liu Y, Zhang L, Zhao J, Lu R, Shao X, Xu K Int J Chron Obstruct Pulmon Dis. 2024; 19:1905-1920.

PMID: 39206144 PMC: 11352541. DOI: 10.2147/COPD.S468825.


Image-guided metabolomics and transcriptomics reveal tumour heterogeneity in luminal A and B human breast cancer beyond glucose tracer uptake.

Yang Q, Deng S, Preibsch H, Schade T, Koch A, Berezhnoy G Clin Transl Med. 2024; 14(2):e1550.

PMID: 38332687 PMC: 10853679. DOI: 10.1002/ctm2.1550.